Quote:

---

Dr Been Question - I think we need to find out what happened to the interim data on the severe covid trial. It was supposed to be 50 patients. He updated that 120 in trial. So the plan seems to have changed - what the new plan.

---

A interim analysis of 120 is far superior to 51. It would be difficult to give FDA approval on 51. When they decided on 51, they didn't know how quickly the trial would enroll. When it was enrolling slow as molasses in May, it made sense to keep the interim analysis at 51. But now that the trial has been enrolling rapidly, it makes sense to delay the interim analysis by a couple of weeks to produce a far more compelling readout. Also, we have enough catalysts in July. There is no need to clump so many together. Let's have the interim analysis of the severe/critical released in August after we have uplisted to the NYSE. It should rocket the stock price to the moon.